Showing results (71-80 of 831) with videos related to
Sort By:
Pageof 84
The Journal of Biological Chemistry|December 17, 2002
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cellsKlaus Podar, Yu-Tzu Tai, Craig E Cole, et al.Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.Cancer Research|April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C AndersonCell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C AndersonCancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C AndersonOncogene|December 4, 2003
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell linesTeru Hideshima, Toshiaki Hayashi, Dharminder Chauhan, et al.Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.Pageof 84